Incyte Corporation
- INCY
- NASDAQ
- Biotechnology
- JAK Inhibitors
- Oncology Therapeutics
- Hematology Drugs
$113.07
Today −0.18%Quote Oct 16, 2026, 08:00 PM UTC
−11.40%over the last month
Max drawdown −14.9%From 1-month high −11.4%3 months −2.2%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$22.92B
Quote Oct 16
Next earnings
Oct 29
Expected, not confirmed
Analyst target
$134.40
+18.9% from here
Floor
$112.85
0.2% below price
Where the price sits
44 analysts
Analyst range, low to high
$104.00$157.00
- Price $113.07
- Resistance $114.40–$115.55
- Consensus $134.40
The price is just above its floor and right under resistance. Analysts' average target sits about 19% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about INCYPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
Q2 2026 revenue $1.67B
- J A K A F I$940.8M56.2%
- OPZELURA$449.7M26.9%
- M I N J U V I$53.7M3.2%
- ZYNYZ$49.9M3.0%
- Olumiant Royalty$38.5M2.3%
- I C L U S I G$34.4M2.1%
- PEMAZYRE Royalty Revenues$23.4M1.4%
- Milestone And Contract Revenue$11.2M0.7%
- Other / not reported$72.3M4.3%
Industry
Biotechnology
Employees
2,844